Home » Stocks » SNSS

Sunesis Pharmaceuticals, Inc. (SNSS)

Stock Price: $2.77 USD -0.21 (-7.05%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $2.78 +0.01 (0.36%) Jan 26, 7:38 PM
Market Cap 51.79M
Revenue (ttm) 2.19M
Net Income (ttm) -22.09M
Shares Out 15.93M
EPS (ttm) -1.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $2.77
Previous Close $2.98
Change ($) -0.21
Change (%) -7.05%
Day's Open 3.03
Day's Range 2.76 - 3.10
Day's Volume 1,133,300
52-Week Range 1.13 - 11.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 weeks ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesi...

PRNewsWire - 1 month ago

NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New...

Business Wire - 1 month ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesi...

GlobeNewsWire - 1 month ago

WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Sunesis Pharmaceuticals, Inc. (“Sunesis”) (NASDAQ CM: SNSS) regarding possible bre...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.

PRNewsWire - 1 month ago

NEW YORK, Nov. 30, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sunesis Pharmaceuticals, Inc....

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) and Viracta Therapeutics, In...

InvestorPlace - 1 month ago

Shares of SNSS stock are climbing higher on Monday after Sunesis Pharmaceuticals announced a merger deal with Viracta Therapeutics. The post Sunesis Pharmaceuticals News: 7 Things for SNSS Sto...

GlobeNewsWire - 1 month ago

Merger to c reate Nasdaq-listed company focused on developing Viracta's precision oncology pipeline targeting virus-associated malignancies

Seeking Alpha - 2 months ago

Sunesis Pharmaceuticals, Inc. (SNSS) Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Sunesis to Host Conference Call Today at 4:30 PM Eastern Time Sunesis to Host Conference Call Today at 4:30 PM Eastern Time

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 a...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecu...

The Motley Fool - 4 months ago

The drugmaker is having to take a last-resort measure to keep its shares listed on the Nasdaq stock exchange.

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor co...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and R...

Seeking Alpha - 5 months ago

Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) were down 4.45% in after-market trading after the company reported Q2 results.

Zacks Investment Research - 5 months ago

Sunesis (SNSS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Sunesis Pharmaceuticals (NASDAQ: SNSS) will be releasing its next round of earnings this Tuesday, August 11.

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 ...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 share...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it intends to offer and sell, subject to market and other con...

Zacks Investment Research - 6 months ago

Is (SNSS) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 6 months ago

Company reduces workforce to focus on development of PDK1 inhibitor, SNS-510 Company reduces workforce to focus on development of PDK1 inhibitor, SNS-510

GlobeNewsWire - 7 months ago

Company Shifting Resources from Vecabrutinib to Development of PDK-1 Inhibitor SNS-510 Company Shifting Resources from Vecabrutinib to Development of PDK-1 Inhibitor SNS-510

Seeking Alpha - 8 months ago

Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Is (SNSS) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 10 months ago

Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Poster to be Presented at Upcoming ASH Annual Meeting Poster to be Presented at Upcoming ASH Annual Meeting

Seeking Alpha - 1 year ago

Sunesis Pharmaceuticals, Inc. (SNSS) Management on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice Preside...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International Con...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Boa...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS).

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice Preside...

Zacks Investment Research - 1 year ago

Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 1 year ago

Sunesis Pharmaceuticals, Inc. (SNSS) Interim CEO Dayton Misfeldt on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Sunesis (SNSS) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q1 20189 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.

About SNSS

Sunesis Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hema... [Read more...]

Industry
Biotechnology
IPO Date
Sep 27, 2005
CEO
Dayton Misfeldt
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
SNSS
Full Company Profile

Financial Performance

In 2019, SNSS's revenue was $2.07 million, an increase of 774.68% compared to the previous year's $237,000. Losses were -$23.33 million, -12.34% less than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SNSS stock is "Hold." The 12-month stock price forecast is 3.25, which is an increase of 17.33% from the latest price.

Price Target
$3.25
(17.33% upside)
Analyst Consensus: Hold